Table 2.
Study characteristics (stent retriever thrombectomy)
| Study [Ref.] | Subjects, n | Period | Country | Design | Mean age ± SD1, years; female gender, n (%) | Device | Stroke severity (NIHSS score) | Additional EVT | IVT | Recanalization (TICI 2b-3)1 | Favorable outcome at 3 months (mRS score 0-2)1 | Mortality at 3 months1 | SICH |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Costalatet al.[12] | 16 | 2009–2010 | France | P, S | NA | Solitaire | ? | 0 | 10 (62%) | 13 (81%)2 | 7 (44%) | 4 (25%) | NA |
| EspinosadeRuedaet al.[13] | 18 | 2010–2012 | Spain | R,S | Median 67.5 (range 32–87); 11 (61) | 13× Solitaire 5× Trevo | Mean 20.43 | 0 | 0 (0%) | 17 (94%) | 9 (50%) | 4 (22%) | NA |
| Lefevreet al. [14] | 25 | 2010–2012 | France | R,S | NA | Solitaire | Mean 19.9 | 9× rtPA | 1 (4%) | 23 (92%) | 14 (56%) | 10 (40%) | NA |
| Mourand et al. [15] | 31 | 2009–2011 | France | R,S | 61±17; 16 (52) | Solitaire | Median 38 (range 9–38)4 | 0 | 19 (61%) | 23 (74%) | 11 (35%)5 | 10 (32%) | <SMALLCAPS> 5 (16%)<UPPER> E</UPPER></SMALLCAPS> |
| Möhlenbruch et al. [16] | 24 | 2009–2012 | Germany | R,S | Median 70 (range 33–83); 7 (29) | 12× Revive 9× Solitaire 2× both | Median 24 (range 7–42) | 6× rtPA | 21 (88%) | 18 (75%) | 8 (33%) | 7 (29%) | 1 (4%,)PII |
| Baek et al. [17] | 25 | 2010–2012 | South Korea | P, S | 68; 11 (44) | Solitaire | Mean 11 | 3× Penumbra 1× urokinase | 6 (24%) | 24 (96%) | 12 (48%) | 3 (12%) | 0 (0%)E |
| Carneiro et al. [18] | 24 | 2012–2014 | Portugal | R,S | 57 (range 27–80); 7 (29) | 21× Trevo 3× Solitaire | Median 20 (range 12–36) | 0 | 11 (46%) | 15 (63%) | 5 (21%) | 8 (33%) | 0 (0%)E |
| Wanget al. [19] | 18 | 2011–2013 | China | R,S | 59.56±10.35; 6 (33) | Solitaire | Median 25.5 (range 20–35)6 | 8×IArtPA | NA | 17 (94%) | 7 (39%) | 5 (28%) | 1×SAH (6%)NS |
| Yoon et al. [20] | 50 | 2010–2015 | South Korea | R,S | 71 (range 63–77); 24 (48) | Solitaire and Trevo | Median 10.5 (IQR 7.75–16) | 6× Penumbra 2* urokinase | 14 (28%) | 48 (96%) | 27 (54%) | 6 (12%) | 0 (0%)NS |
| Goryet al. [21] | 22 | 2010–2014 | France | R,S | Median 60 (range 31–76); 8 (36) | Solitaire | Mean 13.6 (range 4–22, n = 12)7 | 2× rtPA | 8 (36%) | 16 (73%) | 6 (27%) | 10 (46%) | 3 (14%) E@24h |
| Lee et al. [22] | 62 | 2010–2016 | South Korea | R, S | 69.6±11.95 (range 31–76); 26 (42) | Solitaire | Mean (SD) 12.4±6.23 | 11× manual aspiration | 17 (27%) | 60 (97%) | 33 (53%) | 10 (16%) | 1 (2%)E |
| Wen et al. [23] | 19 | 2013–2015 | China | R, S | Median 62 (IQR 56–75); 3 (36) | 16× Solitaire 3× Revive | Median 26 (IQR 14–35) | 4× stenting | 5 (26%) | 17 (89%) | 10 (53%) | 1 (5%) | NA |
| Hu et al. [24] | 24 | 2013–2016 | South Korea | R, S | Median 65.7 (IQR 32–85); 11 (46) | 14× Solitaire 10×Trevo | Mean 14.2 (IQR 2–34) | 0 | 9 (38%) | 19 (79%) | 10 (42%) | 4 (17%) | 1 (4%)NS |
| Combined | 358 | 2008–2016 | NA | NA | 139 (38) | NA | NA | 59 (16%) | 128 (36%) | 310 (88%) | 159 (43 %) | 82 (22%) | 12 (5%) |
R, retrospective; P, prospective; S, single-center; M, multicenter; EVT, endovascular therapy; IVT, intravenous thrombolysis; SICH, symptomatic intracranial hemorrhage; SAH, subarachnoid hemorrhage; rtPA, recombinant tissue plasminogen activator; NA, not applicable; NS, not specified; NIHSS, National Institute of Health Stroke Scale; E, ECASS II criteria; E@24h, ECASS II criteria at 24 h; PII, PROACT II criteria.
If not otherwise specified.
TICI 3.
Baseline NIHSS score not given for intubated patients (n = 4).
Maximum prethrombectomy NIHSS score.
Median 240 days.
Median NIHSS score calculated by individual patient data given in the manuscript.
10 comatose patients; comatose patients were assigned an NIHSS score of 38 [18].